MedTrace Logo

Effect of Glucose Degradation Products (GDP) on Endothelial Dysfunction

NCT01315314 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 146

Last updated 2011-03-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of neutral pH and low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF) on systemic inflammation and endothelial dysfunction markers in incident PD patients.

Conditions

  • Kidney Failure, Chronic
  • Disorders Associated With Peritoneal Dialysis

Interventions

DRUG

Balance, Fresenius Medical Care, Germany

low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF)

Sponsors & Collaborators

  • Ministry of Health & Welfare, Korea

    collaborator OTHER_GOV

  • Fresenius Medical Care Korea

    collaborator INDUSTRY

  • Kyungpook National University Hospital

    lead OTHER

Principal Investigators

  • Yong-Lim Kim, Professor · Kyungpook National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01315314 on ClinicalTrials.gov